The earnings call highlighted strong execution in terms of EXPAREL growth, strategic partnerships, and improved financial metrics, while also addressing challenges such as stagnant sales for some products and increased expenses. Overall, the company demonstrated a positive outlook with strategic initiatives in place to address current challenges.

Company Guidance -

Q3 2025

During the Pacira Biosciences Q2 2025 earnings call, the company provided updated guidance highlighting key financial metrics and strategic initiatives. The revenue guidance for the full year 2025 was narrowed to a range of $730 million to $750 million, with an increase in the non-GAAP gross margin guidance to 78-80%, up from the previous 76-78%. Notable accomplishments included a 6% year-over-year volume growth for EXPAREL, the highest in eight quarters, and a new strategic partnership with Johnson & Johnson MedTech for ZILRETTA. The company improved its capital structure with a $300 million revolving credit facility and executed $50 million in share repurchases. Pacira also reported a significant adjusted EBITDA of $54.3 million for the second quarter and ended the quarter with pro forma cash and investments of approximately $270 million. The call reiterated Pacira's commitment to advancing its 5x30 strategy, which aims for five strategic partnerships by 2030.

EXPAREL Volume Growth

EXPAREL performance improved with a 6% year-over-year volume growth, the highest in 8 quarters.

Reiteration of Revenue Guidance

Pacira reiterated and narrowed its range for revenue guidance, indicating strong commercial progress.

Enhanced Capital Structure

The company enhanced its capital structure and liquidity with a new $300 million revolver and a significant reduction of debt.

Commercial Coverage Expansion

More than 40 million commercial lives now have access to EXPAREL, with plans to reach 60 million by year-end, positioning the company to exit the year with nearly 100 million covered lives across both commercial and government payers.

J&J MedTech Partnership for ZILRETTA

A new partnership with Johnson & Johnson MedTech for ZILRETTA is expected to significantly expand reach and patient access, essentially doubling sales calls for ZILRETTA.

Improved Gross Margins

Second quarter non-GAAP gross margin improved to 82% versus 76% last year, benefiting from improved cost and efficiencies.

Pacira Pharmaceuticals (PCRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PCRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	0.66 / -	0.79	―	―	―
Aug 05, 2025	2025 (Q2)	0.71 / 0.74	0.89	-16.85% (-0.15)
May 08, 2025	2025 (Q1)	0.60 / 0.62	0.62	0.00% (0.00)
Feb 27, 2025	2024 (Q4)	0.83 / 0.91	0.89	2.25% (+0.02)
Nov 06, 2024	2024 (Q3)	0.70 / 0.79	0.72	9.72% (+0.07)	―
Jul 30, 2024	2024 (Q2)	0.70 / 0.89	0.78	14.10% (+0.11)
May 07, 2024	2024 (Q1)	0.62 / 0.62	0.53	16.98% (+0.09)
Feb 29, 2024	2023 (Q4)	0.88 / 0.89	0.8	11.25% (+0.09)
Nov 02, 2023	2023 (Q3)	0.78 / 0.72	0.64	12.50% (+0.08)
Aug 02, 2023	2023 (Q2)	0.76 / 0.78	0.51	52.94% (+0.27)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PCRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$22.54	$22.40	-0.62%
May 08, 2025	$24.91	$25.12	+0.84%
Feb 27, 2025	$25.38	$24.05	-5.24%
Nov 06, 2024	$17.67	$17.70	+0.17%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pacira Pharmaceuticals (PCRX) report earnings?

Pacira Pharmaceuticals (PCRX) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Pacira Pharmaceuticals (PCRX) earnings time?

Pacira Pharmaceuticals (PCRX) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PCRX EPS forecast?

PCRX EPS forecast for the fiscal quarter 2025 (Q3) is 0.66.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing